Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey

International Journal of Cardiology

Volumn 156, Issue 1, 2012, Pages 69-75

  Cayla, Guillaume ^a   Collet, Jean Philippe ^a   Silvain, Johanne ^a   Thiefin, Gérard ^b   Woimant, France ^c   Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Gastroenterology Department   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aspirin; Compliance; Gastrointestinal symptoms

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT;

ADL DISABILITY; ADULT; AEROPHAGIA; AGE DISTRIBUTION; AGED; ARTICLE; ATTITUDE TO ILLNESS; BELCHING; BLOATING; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DYSPEPSIA; DYSPHAGIA; EARLY SATIETY; EPIGASTRIC DISCOMFORT; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENDER; HEARTBURN; HIATUS HERNIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; UPPER GASTROINTESTINAL SYMPTOM;

AGED; AGED, 80 AND OVER; ASPIRIN; FEMALE; GASTROINTESTINAL DISEASES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84858078199     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.027     Document Type: Article

References (50)

1. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration Bmj 308 6921 Jan 8 1994 81 106
2. C.L. Campbell, S. Smyth, G. Montalescot, and S.R. Steinhubl Aspirin dose for the prevention of cardiovascular disease: a systematic review Jama 297 18 May 9 2007 2018 2024 (Pubitemid 46740354)
3. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 3 Jul 20 1989 129 135
4. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, and S. Julius Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 9118 Jun 13 1998 1755 1762 (Pubitemid 28269185)
5. G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project Lancet 357 9250 Jan 13 2001 89 95
6. A. Zanchetti, L. Hansson, B. Dahlof, S. Julius, J. Menard, and I. Warnold Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk J Hypertens 20 11 Nov 2002 2301 2307 (Pubitemid 35388250)
7. M. Sacco, F. Pellegrini, M.C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diab Care 26 12 Dec 2003 3264 3272 (Pubitemid 37466885)
8. P.M. Ridker, N.R. Cook, I.M. Lee, D. Gordon, J.M. Gaziano, and J.E. Manson A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 13 Mar 31 2005 1293 1304
9. J. Belch, A. MacCuish, I. Campbell, S. Cobbe, R. Taylor, and R. Prescott The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease Bmj 337 2008 a1840
10. H. Ogawa, M. Nakayama, T. Morimoto, S. Uemura, M. Kanauchi, and N. Doi Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial Jama 300 18 Nov 12 2008 2134 2141
11. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 9678 May 30 2009 1849 1860
12. M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, and T.J. Walley Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients Bmj 329 7456 Jul 3 2004 15 19 (Pubitemid 38869995)
13. B. Cryer, and M. Feldman Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans Gastroenterology 117 1 Jul 1999 17 25 (Pubitemid 29297615)
14. P.J. Roderick, H.C. Wilkes, and T.W. Meade The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials Br J Clin Pharmacol 35 3 Mar 1993 219 226 (Pubitemid 23074044)
15. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group N Engl J Med 325 18 Oct 31 1991 1261 1266
16. J. Weil, D. Colin-Jones, M. Langman, D. Lawson, R. Logan, and M. Murphy Prophylactic aspirin and risk of peptic ulcer bleeding Bmj 310 6983 Apr 1 1995 827 830
17. N.D. Yeomans, A.I. Lanas, N.J. Talley, A.B. Thomson, R. Daneshjoo, and B. Eriksson Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin Aliment Pharmacol Ther 22 9 Nov 1 2005 795 801 (Pubitemid 41564359)
18. A. Shiotani, T. Kamada, and K. Haruma Low-dose aspirin-induced gastrointestinal diseases: past, present, and future J Gastroenterol 43 8 2008 581 588
19. T.M. MacDonald, S.V. Morant, G.C. Robinson, M.J. Shield, M.M. McGilchrist, and F.E. Murray Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study Bmj 315 7119 Nov 22 1997 1333 1337 (Pubitemid 27499736)
20. P. Wolkenstein, J.J. Grob, S. Bastuji-Garin, S. Ruszczynski, J.C. Roujeau, and J. Revuz French people and skin diseases: results of a survey using a representative sample Arch Dermatol 139 12 Dec 2003 1614 1619 discussion 9 (Pubitemid 37523081)
21. M.A. Charles, E. Eschwege, and A. Basdevant Monitoring the obesity epidemic in France: the Obepi surveys 1997-2006 Obes Silver Spring 16 9 Sep 2008 2182 2186
22. J.C. Deville, C.E. Sarndal, and O. Sautory Generalized raking procedures in survey sampling J Am Stat Assoc 88 1993 1013 1020
23. Institut National des Statistiques et des Etudes Economiques (INSEE). Enquête sur l'emploi. 2002;5.
24. C. Melloni, K.P. Alexander, F.S. Ou, N.M. LaPointe, M.T. Roe, and L.K. Newby Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome Am J Cardiol 104 2 Jul 15 2009 175 181
25. J.P. Collet, G. Montalescot, B. Blanchet, M.L. Tanguy, J.L. Golmard, and R. Choussat Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes Circulation 110 16 Oct 19 2004 2361 2367 (Pubitemid 39407340)
26. E. Ferrari, M. Benhamou, P. Cerboni, and B. Marcel Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis J Am Coll Cardiol 45 3 Feb 1 2005 456 459 (Pubitemid 40186800)
27. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, and F. Burzotta A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease Eur Heart J 27 22 Nov 2006 2667 2674 (Pubitemid 44729867)
28. K.A. Schwartz, D.E. Schwartz, K. Ghosheh, M.J. Reeves, K. Barber, and A. DeFranco Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction Am J Cardiol 95 8 Apr 15 2005 973 975 (Pubitemid 40487749)
29. T. Cuisset, C. Frere, J. Quilici, B. Gaborit, L. Bali, and R. Poyet Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting Am Heart J 157 5 May 2009 889 893
30. M.J. Eisenberg, P.R. Richard, D. Libersan, and K.B. Filion Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents Circulation 119 12 Mar 31 2009 1634 1642
31. Y. Niv, A. Battler, G. Abuksis, E. Gal, B. Sapoznikov, and A. Vilkin Endoscopy in asymptomatic minidose aspirin consumers Dig Dis Sci 50 1 Jan 2005 78 80 (Pubitemid 40379143)
32. F.K. Chan, J.Y. Ching, L.C. Hung, V.W. Wong, V.K. Leung, and N.N. Kung Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding N Engl J Med 352 3 Jan 20 2005 238 244 (Pubitemid 40110812)
33. A.S. Taha, C. McCloskey, R. Prasad, and V. Bezlyak Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial Lancet 374 9684 Jul 11 2009 119 125
34. N. Yeomans, A. Lanas, J. Labenz, S.V. van Zanten, C. van Rensburg, and I. Racz Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin Am J Gastroenterol 103 10 Oct 2008 2465 2473
35. D.L. Bhatt, J. Scheiman, N.S. Abraham, E.M. Antman, F.K. Chan, and C.D. Furberg ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation 118 18 Oct 28 2008 1894 1909
36. A. Lanas, J. Fuentes, R. Benito, P. Serrano, E. Bajador, and R. Sainz Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin Aliment Pharmacol Ther 16 4 Apr 2002 779 786 (Pubitemid 34407526)
37. W.A. Stack, J.C. Atherton, G.M. Hawkey, R.F. Logan, and C.J. Hawkey Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding Aliment Pharmacol Ther 16 3 Mar 2002 497 506 (Pubitemid 34214529)
38. J.L. Wallace, W. McKnight, B.K. Reuter, and N. Vergnolle NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2 Gastroenterology 119 3 Sep 2000 706 714
39. N.S. Abraham, C. Hartman, D. Castillo, P. Richardson, and W. Smalley Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users Am J Gastroenterol 103 2 Feb 2008 323 332 (Pubitemid 351248716)
40. V. Strand Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370 9605 Dec 22 2007 2138 2151 (Pubitemid 350296305)
41. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study Jama 284 10 Sep 13 2000 1247 1255
42. T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, and E. Ehrsam Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial Lancet 364 9435 Aug 21-27 2004 665 674
43. R.A. Moore, S. Derry, G.T. Makinson, and H.J. McQuay Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports Arthritis Res Ther 7 3 2005 R644 R665
44. A. Rostom, P. Moayyedi, and R. Hunt Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks Aliment Pharmacol Ther 29 5 Mar 1 2009 481 496
45. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 7 Aug 16 2001 494 502 (Pubitemid 32758501)
46. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, and M. Kaste Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 9431 Jul 24-30 2004 331 337
47. D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, and W.E. Boden Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 16 Apr 20 2006 1706 1717
48. S. Mise, A. Tonkic, V. Pesutic, M. Tonkic, S. Mise, and V. Capkun The presentation and organization of adaptive cytoprotection in the rat stomach, duodenum, and colon. Dedicated to Andre Robert the founder of the concept of cytoprotection and adaptive cytoprotection Med Sci Monit 12 4 Apr 2006 BR146 BR153
49. A. Robert Cytoprotection by prostaglandins Gastroenterology 77 4 Pt 1 Oct 1979 761 767 (Pubitemid 9257866)
50. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150